Research and Markets: European Cystic Fibrosis Market 2015-2019 - Key Vendors are Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals
Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
UPDATE: Biotech stocks on pace to snap 8-day win streak as warnings abound
UPDATE: Chesapeake shares rise after capex budget trimmed
ESSA Pharma Inc. Announces Appointment of New Director
Research and Markets: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success
Options on this firm's blockbuster cost a little but pay off big.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
We dive into the process for adding companies and booting them from the iconic index.